DrugPatentWatch Database Preview
ARMONAIR RESPICLICK Drug Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
Which patents cover Armonair Respiclick, and when can generic versions of Armonair Respiclick launch?
Armonair Respiclick is a drug marketed by Teva Pharm and is included in one NDA. There are sixteen patents protecting this drug.
This drug has three hundred and seventy patent family members in thirty-three countries.
The generic ingredient in ARMONAIR RESPICLICK is fluticasone propionate. There are twenty-nine drug master file entries for this compound. Seventy-four suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.
US ANDA Litigation and Generic Entry Outlook for Armonair Respiclick
A generic version of ARMONAIR RESPICLICK was approved as fluticasone propionate by ANDA REPOSITORY on January 24th, 2020.
Summary for ARMONAIR RESPICLICK
| International Patents: | 370 |
| US Patents: | 16 |
| Applicants: | 1 |
| NDAs: | 1 |
| Bulk Api Vendors: | 68 |
| Patent Applications: | 6,336 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ARMONAIR RESPICLICK |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ARMONAIR RESPICLICK |
| DailyMed Link: | ARMONAIR RESPICLICK at DailyMed |
Recent Litigation for ARMONAIR RESPICLICK
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Teva Branded Pharmaceutical Products R&D Inc. v. Perrigo Pharmaceuticals Co. | 2013-08-16 |
Synonyms for ARMONAIR RESPICLICK
| (1R,2S,8S,10S,11S,13R,14R,15S,17S)-1,8-difluoro-14-{[(fluoromethyl)sulfanyl]carbonyl}-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-3,6-dien-14-yl propanoate |
| (6?,11?,16?,17?)-6,9-Difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic acid fluoromethyl ester |
| (6alpha,11beta,16alpha,17alpha)-6,9-Difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic acid S-(fluoromethyl) ester |
| [(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate |
| 474F142 |
| 6alpha,9-difluoro-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-11beta-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17alpha-yl propanoate |
| 80474-14-2 |
| AB00513992 |
| AB00513992_08 |
| AB00513992-06 |
| AB1010912 |
| AC-457 |
| AC1L9FLD |
| AJ-47435 |
| AKOS015895220 |
| AN-584/43505443 |
| Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, (6alpha,11beta,16alpha,17alpha)-S-(fluoromethyl) ester |
| Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, S-(fluoromethyl) ester, (6-alpha,11-beta,16-alpha,17-alpha)- |
| ArmonAir RespiClickTM |
| Asmatil |
| atemur |
| Axotide |
| BC216013 |
| BDBM50354849 |
| BIF0710 |
| BPBio1_001203 |
| BR-72799 |
| BRD-K62310379-001-03-0 |
| Brethal |
| BSPBio_001093 |
| C25H31F3O5S |
| CCG-100981 |
| CCI 18781 |
| CCI-18781 |
| CHEBI:31441 |
| CHEMBL1473 |
| CS-1986 |
| Cultivate |
| Cutivate |
| Cutivate (TN) |
| D01708 |
| DB00588 |
| Flixonase |
| Flixonase Nasal Spray |
| Flixotide |
| Flixotide Disk |
| Flixotide Disks |
| Flixotide Inhaler |
| Flonase |
| Flonase (TN) |
| Flonase Allergy Relief |
| Flonase Aq |
| Flovent |
| Flovent (TN) |
| Flovent Diskus |
| Flovent Diskus 100 |
| Flovent Diskus 250 |
| Flovent Diskus 50 |
| Flovent HFA |
| Flovent Rotadisk |
| Flovent-hfa |
| Fluinol |
| Flunase |
| Flusonal |
| Fluspiral |
| Fluticasone (propionate) |
| Fluticasone Impurity B |
| FLUTICASONE PROPIONATE |
| Fluticasone propionate (Flonase, Veramyst) |
| Fluticasone propionate (JAN/USAN) |
| Fluticasone propionate [USAN:USP] |
| Fluticasone propionate [USAN] |
| Fluticasone propionate for impurity C identification, EuropePharmacopoeia (EP) Reference Standard |
| Fluticasone propionate for impurity G identification, EuropePharmacopoeia (EP) Reference Standard |
| Fluticasone propionate, >=98% (HPLC), powder |
| Fluticasone propionate, European Pharmacopoeia (EP) Reference Standard |
| Fluticasone Propionate, Pharmaceutical Secondary Standard; Certified Reference Material |
| Fluticasone propionate, United States Pharmacopeia (USP) Reference Standard |
| Fluticasonpropionat Allen |
| Flutide |
| Flutivate |
| Fluxonal |
| FN-25 |
| FT-0082893 |
| GTPL7080 |
| HMS1571G15 |
| HMS2051N19 |
| HMS2098G15 |
| HMS3715G15 |
| HY-B0154 |
| Inalacor |
| KS-1173 |
| LS-19323 |
| MFCD00866007 |
| MLS001424085 |
| MolPort-003-847-468 |
| NC00231 |
| NCGC00179308-01 |
| NCGC00179308-05 |
| O2GMZ0LF5W |
| Prestwick0_000997 |
| Prestwick1_000997 |
| Prestwick2_000997 |
| Prestwick3_000997 |
| Q-101393 |
| Rinosone |
| RS0009 |
| S-(Fluoromethyl) 6alpha,9-difluoro-11beta,17-dihydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta-carbothioate, 17-propionate |
| S-(fluoromethyl)-6,9-difluoro-11,17-dihydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carbothioate,17-propionate |
| s1992 |
| SC-19333 |
| SCHEMBL4068 |
| Skyron |
| SMR000469159 |
| SPBio_002984 |
| SR-01000763355 |
| SR-01000763355-3 |
| ST2407016 |
| Trialona |
| Ubizol |
| UNII-O2GMZ0LF5W |
| WMWTYOKRWGGJOA-CENSZEJFSA-N |
| Xhance |
| ZINC3920027 |
| Zoflut |
US Patents and Regulatory Information for ARMONAIR RESPICLICK
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharm | ARMONAIR RESPICLICK | fluticasone propionate | POWDER;INHALATION | 208798-003 | Jan 27, 2017 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Teva Pharm | ARMONAIR RESPICLICK | fluticasone propionate | POWDER;INHALATION | 208798-002 | Jan 27, 2017 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Teva Pharm | ARMONAIR RESPICLICK | fluticasone propionate | POWDER;INHALATION | 208798-003 | Jan 27, 2017 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Teva Pharm | ARMONAIR RESPICLICK | fluticasone propionate | POWDER;INHALATION | 208798-003 | Jan 27, 2017 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Teva Pharm | ARMONAIR RESPICLICK | fluticasone propionate | POWDER;INHALATION | 208798-003 | Jan 27, 2017 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Teva Pharm | ARMONAIR RESPICLICK | fluticasone propionate | POWDER;INHALATION | 208798-002 | Jan 27, 2017 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ARMONAIR RESPICLICK
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Teva Pharm | ARMONAIR RESPICLICK | fluticasone propionate | POWDER;INHALATION | 208798-003 | Jan 27, 2017 | Start Trial | Start Trial |
| Teva Pharm | ARMONAIR RESPICLICK | fluticasone propionate | POWDER;INHALATION | 208798-001 | Jan 27, 2017 | Start Trial | Start Trial |
| Teva Pharm | ARMONAIR RESPICLICK | fluticasone propionate | POWDER;INHALATION | 208798-002 | Jan 27, 2017 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ARMONAIR RESPICLICK
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2013509923 | Start Trial |
| Japan | 4897569 | Start Trial |
| Uruguay | 26793 | Start Trial |
| South Africa | 201307991 | Start Trial |
| European Patent Office | 1330280 | Start Trial |
| New Zealand | 627544 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ARMONAIR RESPICLICK
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1519731 | 92269 | Luxembourg | Start Trial | PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE |
| 1305329 | SPC/GB08/026 | United Kingdom | Start Trial | PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080111; UK EU/1/07/434/002 20080111; UK EU/1/07/434/003 20080111 |
| 2506844 | 2018C/022 | Belgium | Start Trial | PRODUCT NAME: EEN FARMACEUTISCH COMBINATIEPRODUCT DAT EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN UMECLIDINIUM (BV. UMECLIDINIUMBROMIDE), VILANTEROL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN (BV. VILANTEROLTRIFENATAAT) EN FLUTICASONEFUROAAT OMVAT; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117 |
| 2506844 | 1890025-8 | Sweden | Start Trial | PRODUCT NAME: COMBINATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF (E.G. VILANTEROL TRIFENATATE) AND FLUTICASONE FUROATE.; REG. NO/DATE: EU/1/17/1236 20171117 |
| 2506844 | LUC00077 | Luxembourg | Start Trial | PRODUCT NAME: PRODUIT DE COMBINAISON PHARMACEUTIQUE COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (PAR EXEMPLE LE BROMURE D'UMECLIDINIUM), LE VILANTEROL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE (PAR EXEMPLE LE TRIFENATATE DE VILANTEROL) ET LE FUROATE DE FLUTICASONE; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117 |
| 1519731 | 13C0067 | France | Start Trial | PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
